Antiplatelet Management for Epidural Steroid Injections
For most epidural steroid injection approaches, aspirin can be safely continued, while P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) should be held for 5-7 days before the procedure—but this decision must be weighed against the patient's thrombotic risk, particularly in those with recent coronary stents.
Risk-Based Approach to Antiplatelet Management
The management strategy depends on two critical assessments:
1. Procedure Bleeding Risk Classification
Low-Risk Procedures (can proceed on antiplatelet therapy):
- Lumbar transforaminal epidural steroid injections
- Caudal epidural steroid injections
- Sacroiliac joint injections
- Lumbar medial branch blocks and radiofrequency neurotomy
Intermediate-Risk Procedures (aspirin can continue, hold P2Y12 inhibitors):
- Lumbar interlaminar epidural steroid injections
- Cervical and thoracic interlaminar epidural steroid injections
High-Risk Procedures (consider holding all antiplatelets):
- Cervical transforaminal epidural steroid injections (controversial—some experts classify as intermediate risk)
2. Patient Thrombotic Risk Assessment
High Thrombotic Risk (strongly favor continuing antiplatelets):
- Drug-eluting stent placed <12 months ago
- Bare metal stent placed <1 month ago
- Recent acute coronary syndrome (<6 weeks)
- History of stent thrombosis
- Multiple stents or complex coronary anatomy
Moderate-to-Low Thrombotic Risk:
- Drug-eluting stent >12 months ago
- Bare metal stent >1 month ago
- Stable coronary disease on single antiplatelet agent
Specific Antiplatelet Recommendations
Aspirin (81-325 mg daily)
- Continue for all low and intermediate-risk procedures 1
- Only consider holding for high-risk procedures with low thrombotic risk
- The evidence from multiple retrospective studies shows no epidural hematomas in patients continuing aspirin 2, 3, 4, 5
P2Y12 Inhibitors (Clopidogrel, Prasugrel, Ticagrelor)
For patients on dual antiplatelet therapy (DAPT):
- Maintain aspirin, hold P2Y12 inhibitor for 5 days (clopidogrel, ticagrelor) or 7 days (prasugrel) before intermediate-risk procedures 6, 7
- For low-risk procedures (lumbar transforaminal, caudal, medial branch blocks), consider continuing both agents if thrombotic risk is high 2, 4, 5
- Resume P2Y12 inhibitor as soon as possible post-procedure, ideally within 24 hours 6
Critical timing considerations:
Evidence-Based Safety Data
Recent retrospective studies provide reassuring safety data:
- Zero epidural hematomas in 275 consecutive spine injections performed while continuing antiplatelet/anticoagulant therapy 2
- Zero clinically relevant bleeding events in 591 cervical/thoracic interlaminar epidurals (240 patients maintained antiplatelets) 3
- Zero complications in 443 caudal epidurals performed on antithrombotic therapy 5
- Zero bleeding events in 197 injection sites across multiple approaches in patients on antiplatelets 4
Critical Pitfalls to Avoid
Never stop both antiplatelet agents simultaneously in patients with recent coronary stents—this dramatically increases stent thrombosis risk, which carries 45% mortality 8, 7
Coordinate with cardiology for any patient with drug-eluting stent <12 months or bare metal stent <1 month before considering P2Y12 inhibitor cessation 8, 7
The risk of stopping antiplatelets may exceed bleeding risk for most epidural approaches—multiple studies show catastrophic cardiovascular events from antiplatelet cessation 9, 5, 10
Don't automatically defer procedures—postponing necessary pain interventions in high-thrombotic-risk patients to allow antiplatelet washout may cause more harm than benefit 10
Practical Algorithm
Step 1: Classify procedure risk (low/intermediate/high bleeding risk)
Step 2: Assess thrombotic risk (recent stent? ACS? stroke history?)
Step 3: Apply management:
- Low-risk procedure + any thrombotic risk → Continue all antiplatelets
- Intermediate-risk procedure + high thrombotic risk → Continue aspirin, consider continuing P2Y12 inhibitor
- Intermediate-risk procedure + low thrombotic risk → Continue aspirin, hold P2Y12 inhibitor 5-7 days
- High-risk procedure → Multidisciplinary discussion; if must proceed, maintain aspirin if possible, hold P2Y12 inhibitor 5-7 days
Step 4: Resume P2Y12 inhibitors within 24 hours post-procedure when hemostasis achieved 6
The growing body of evidence suggests that continuing antiplatelet therapy for most epidural steroid injection approaches is safer than the thrombotic risk of cessation 2, 3, 4, 5, 10.